Scholarlink

<p>Despite the increasing number of available antiseizure medications (ASMs), optimal medical therapy is still a process of trial and error. We aimed to predict the responsiveness of various ASMs based on initial tests using artificial intelligence. The study consisted of 2586 patients fulfilling the following criteria: (1) first visit to the epileptologists from 2008 to 2017, (2) a diagnosis of epilepsy, and 3) ≥ three years of follow-up duration. The clinical characteristics, ASM history, seizure frequency, laboratory, EEG, and MRI results, were collected. Machine algorithms were utilized to predict the responsiveness of specific regimens. Valproate showed the highest area under curve (AUC), 0.686. The AUCs of levetiracetam, oxcarbazepine, and lamotrigine were 0.614, 0.633, and 0.674. The AUCs of common dual regimens were 0.543 for levetiracetam + oxcarbazepine, 0.454 for levetiracetam + valproate, and 0.583 for levetiracetam + lamotrigine. Levetiracetam + carbamazepine showed the highest AUC, 0.764. In Shapley Additive exPlanations analysis, seizure type significantly impacted prediction performance for valproate responsiveness, and onset age and disease duration for lamotrigine. The prediction performances for the response based on initial data differ according to ASMs. An enormous dataset from a multicenter would improve the prediction power of ASM responsiveness in the future.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Prediction of personalized antiseizure medications response based on clinical signatures in epilepsy

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年9月26日

查看全文
  • Kyung-Il Park,
  • Youmin Shin,
  • Sungeun Hwang,
  • Yong-Jeong Kim,
  • Seung-Bo Lee,
  • Hyoshin Son,
  • Jangsup Moon,
  • Soon-Tae Lee,
  • Keun-Hwa Jung,
  • Kon Chu,
  • Ki-Young Jung,
  • Young-Gon Kim,
  • Sang Kun Lee

摘要

Despite the increasing number of available antiseizure medications (ASMs), optimal medical therapy is still a process of trial and error. We aimed to predict the responsiveness of various ASMs based on initial tests using artificial intelligence. The study consisted of 2586 patients fulfilling the following criteria: (1) first visit to the epileptologists from 2008 to 2017, (2) a diagnosis of epilepsy, and 3) ≥ three years of follow-up duration. The clinical characteristics, ASM history, seizure frequency, laboratory, EEG, and MRI results, were collected. Machine algorithms were utilized to predict the responsiveness of specific regimens. Valproate showed the highest area under curve (AUC), 0.686. The AUCs of levetiracetam, oxcarbazepine, and lamotrigine were 0.614, 0.633, and 0.674. The AUCs of common dual regimens were 0.543 for levetiracetam + oxcarbazepine, 0.454 for levetiracetam + valproate, and 0.583 for levetiracetam + lamotrigine. Levetiracetam + carbamazepine showed the highest AUC, 0.764. In Shapley Additive exPlanations analysis, seizure type significantly impacted prediction performance for valproate responsiveness, and onset age and disease duration for lamotrigine. The prediction performances for the response based on initial data differ according to ASMs. An enormous dataset from a multicenter would improve the prediction power of ASM responsiveness in the future.